Federal health officials are moving to restrict a synthetic opioid compound derived from kratom due to serious abuse potential. The substance, 7-hydroxymitragynine (7-OH), is currently available in various consumer products despite lacking FDA approval.
The Department of Health and Human Services announced their
recommendation on June 29 to classify 7-OH under the Controlled Substances Act, citing its powerful opioid properties that can exceed morphine’s potency. While 7-OH occurs naturally in minimal amounts in the kratom plant, products on the market contain enhanced
concentrations of the compound.
These items, which include gummies, tablets, and drink mixes, are frequently marketed deceptively as kratom products according to the FDA. The agency warns that 7-OH has been “engineered to be addictive” and functions as a “potent opioid by design.” Users have reported serious adverse effects including dependency, withdrawal symptoms, overdose incidents, and fatalities.
FDA Commissioner Marty Makary expressed concern about 7-OH potentially triggering another wave of opioid abuse, emphasizing the need for both regulation and public education. The compound’s widespread
availability in corner stores, vape shops, and online retailers has particularly alarmed officials, especially regarding access by young people.
While kratom itself has traditionally been used in Southeast Asia for pain relief and other therapeutic purposes, this synthetic derivative has drawn scrutiny from regulators. Kratom advocates have resisted previous regulatory efforts, maintaining that natural kratom provides a safer alternative to conventional opioids for managing pain and addiction.
The FDA stresses that 7-OH lacks approval for treating any medical conditions, including pain, anxiety, depression, or withdrawal symptoms from opioids or antidepressants. Products containing the compound may not properly disclose its presence or concentration.
HHS Secretary Robert F. Kennedy Jr. revealed discussions with the Attorney General and DEA officials about 7-OH’s concerning spread to vape shops near military installations, schools, and disadvantaged neighborhoods. Senator Markwayne Mullin (R-Okla.) shared a personal account of how such legally available substances can threaten recovery for those with substance use disorders.
The DEA will review the recommendation for rescheduling 7-OH under federal controlled substance regulations. If approved, implementation would follow the agency’s formal rulemaking process. The FDA anticipates 7-OH may be classified as Schedule I, though the final determination rests with the DEA.
The FDA plans to release a detailed report examining 7-OH’s unique properties and associated risks. The agency emphasizes that its focus remains on the concentrated synthetic compound rather than natural kratom products.
This regulatory action reflects mounting concern over the substance’s addictive potential, stemming from its ability to bind with brain opioid receptors. Officials worry about deceptive marketing practices and inadequate labeling that may obscure 7-OH content, particularly in products that could appeal to younger consumers through fruit flavors and familiar formats like gummies and ice cream cones.
The pending restrictions aim to address what health authorities view as an emerging public health threat, while maintaining access to traditional kratom. The move highlights ongoing challenges in regulating novel psychoactive substances that emerge in the consumer marketplace before proper safety evaluation.